About Qrumpharma
Qrumpharma is a Healthcare company based in Doylestown (United States) founded in 2014, and was acquired by MannKind Corp in December 2020. Therapeutics for diabetes and respiratory disorders are developed. The company was acqui-hired. Its focus areas include Life Sciences, Diabetes, Drugs and Pulmonology. Its competitors include Kriya Therapeutics, Sana Biotechnology and Semma Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Qrumpharma was founded in 2014 and is based in Doylestown, United States. Operations are centered in the pharmaceutical sector, where therapeutics for diabetes and respiratory disorders are developed. Products such as Afrezza and Pediatric Afrezza Inhalation Powder are provided for diabetes mellitus treatment, while Thyquidity levothyroxine solution is offered for hypothyroidism. Additional items include Tyvaso DPI for pulmonary hypertension and Cannabidiol Technosphere for panic attacks.
- Headquarters Doylestown, United States
- Stage Acquired
- SectorsHealthcare
- Website qrumpharma.com
- Acquired by MannKind Corp (Dec 2020)
- Investors
- Acquired byMannKind Corp
(Dec 2020)
Investors in Qrumpharma
Qrumpharma has secured backing from 1 investor. Prominent investors backing the company include MannKind Corp.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of small-molecule drugs | 1991 | mannkindcorp.com | Los Angeles, United States |
Investor details for Qrumpharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Qrumpharma
2 dated milestones of Qrumpharma across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Qrumpharma is founded.
- Exit Acquired by MannKind Corp.
Competitors of Qrumpharma
Qrumpharma has 3 listed competitors in our database, 3 of them funded. They include Kriya Therapeutics, Sana Biotechnology and Semma Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| semma-tx.com | 2015 | Cambridge, United States | $158M | 58 | Provider of bio-artificial pancreas for Type 1 Diabetes treatment |
Detailed competitors of Qrumpharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Diabetes
3 companies that operate in the same segment as Qrumpharma (Diabetes) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Qrumpharma
Complete news archive for Qrumpharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Qrumpharma
Qrumpharma was founded in 2014.
Qrumpharma is headquartered in Doylestown, United States. It is registered at Doylestown, Pennsylvania, United States.
Qrumpharma was founded in 2014 and is based in Doylestown, United States. Operations are centered in the pharmaceutical sector, where therapeutics for diabetes and respiratory disorders are developed. Products such as Afrezza and Pediatric Afrezza Inhalation Powder are provided for diabetes mellitus treatment, while Thyquidity levothyroxine solution is offered for hypothyroidism. Additional items include Tyvaso DPI for pulmonary hypertension and Cannabidiol Technosphere for panic attacks.
Qrumpharma's top competitors include Sana Biotechnology, Semma Therapeutics and Kriya Therapeutics.
Qrumpharma has 1 investor. Key investors include MannKind Corp.
Yes. Qrumpharma was acquired by MannKind Corp in December 2020.